ABI
CELG

Adamant Biomedical Investments’s Celgene Corp CELG Stock Holding History

Adamant Biomedical Investments’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$20.8M Sell
186,170
-20,550
-10% -$2.17M 4.98% 1
2014
Q3 		$19.6M Buy
+206,720
New +$18.7M 4.89% 2

Other funds holding CELG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Adamant Biomedical Investments's CELG Position: Q4 2014 in Review

Adamant Biomedical Investments reduced its Celgene Corp (CELG) stake by 9.9% in Q4 2014, selling an estimated $2.17M and leaving 186,170 shares worth $20.8M. The position accounts for 4.98% of the portfolio, ranked #1.

Adamant Biomedical Investments first reported a position in CELG in Q3 2014 and has held it in 2 quarters since. 1,161 funds tracked by Wall St. Rank hold CELG as of Q4 2014.

  • Adamant Biomedical Investments held 186,170 shares of Celgene Corp worth $20.8M as of Q4 2014.
  • Adamant Biomedical Investments sold 20,550 Celgene Corp shares in Q4 2014, an estimated $2.17M.
  • Celgene Corp made up 4.98% of Adamant Biomedical Investments's portfolio in Q4 2014, its #1 holding.
  • Adamant Biomedical Investments first reported a position in Celgene Corp in Q3 2014 and has held it in 2 quarters since.
  • 1,161 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.